Evaluation of Mcl-1 Inhibitors in Preclinical Models of Multiple Myeloma

被引：2
|
作者：
Belmonte, Matthew A. [1 ]
Adam, Ammar [1 ]
Borrelli, Deanna [1 ]
Bhavsar, Deepa [1 ]
Bebernitz, Christina [1 ]
Hird, Alexander [1 ]
Secrist, Paul [1 ]
机构：
[1] AstraZeneca, Waltham, MA USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.3428.3428
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use
    Brennan, Margs S.
    Chang, Catherine
    Tai, Lin
    Lessene, Guillaume
    Strasser, Andreas
    Dewson, Grant
    Kelly, Gemma L.
    Herold, Marco J.
    BLOOD, 2018, 132 (15) : 1573 - 1583
  • [2] MiRNA137 Mimics Targeting MCL-1 as a Novel Therapeutic Agent in Preclinical Models of Multiple Myeloma
    Yang, Y.
    Saha, M. N.
    Chen, Y.
    Chang, H.
    LABORATORY INVESTIGATION, 2014, 94 : 468A - 469A
  • [3] MiRNA137 Mimics Targeting MCL-1 as a Novel Therapeutic Agent in Preclinical Models of Multiple Myeloma
    Yang, Y.
    Saha, M. N.
    Chen, Y.
    Chang, H.
    MODERN PATHOLOGY, 2014, 27 : 468A - 469A
  • [4] Preclinical evaluation of novel MCL-1 degrader in in vitro and in vivo cancer models
    Kowalczyk, P.
    Tomczyk, T.
    Arenciba, J.
    Milewicz, M.
    Skalska, J.
    Trebicka, D.
    Poniatowska, K.
    Adamczyk, J.
    Wojcik, K.
    Cottens, S.
    Dobrzanski, P.
    Bista, M.
    Brach, K.
    Drewniak-Switalska, M.
    Tracz, A.
    Pastok, M.
    Gorecka, K.
    Chrzanowska, K.
    Kaczanowska, K.
    Walczak, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S1443 - S1443
  • [5] Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
    Al-Odat, O. S.
    von Suskil, M.
    Chitren, R. J.
    Elbezanti, W. O.
    Srivastava, S. K.
    Budak-Alpddogan, T.
    Jonnalagadda, S. C.
    Aggarwal, B. B.
    Pandey, M. K.
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [6] Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
    Al-Odat, Omar
    von Suskil, Max
    Chitren, Robert
    Elbezanti, Weam
    Srivastava, Sandeep
    Budak-Alpddogan, Tulin
    Jonnalagadda, Subash
    Aggarwal, Bharat
    Pandey, Manoj
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [7] Mcl-1 regulation and its role in multiple myeloma
    Le Gouill, S
    Podar, K
    Harousseau, JL
    Anderson, KC
    CELL CYCLE, 2004, 3 (10) : 1259 - 1262
  • [8] Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
    Algarin, Esperanza M.
    Diaz-Tejedor, Andrea
    Mogollon, Pedro
    Hernandez-Garcia, Susana
    Corchete, Luis A.
    San-Segundo, Laura
    Martin-Sanchez, Montserrat
    Gonzalez-Mendez, Lorena
    Schoumacher, Marie
    Banquet, Seprimebastien
    Kraus-Berthier, Laurence
    Kloos, Ioana
    Derreal, Alix
    Halilovic, Ensar
    Maacke, Heiko
    Gutierrez, Norma C.
    Mateos, Maria-Victoria
    Paino, Teresa
    Garayoa, Mercedes
    Ocio, Enrique M.
    HAEMATOLOGICA, 2020, 105 (03)
  • [9] MCL1 Inhibitors in Multiple Myeloma
    Vanderkerken, Karin
    De Veirman, Kim
    Maes, Ken
    Menu, Eline
    De Bruyne, Elke
    BLOOD, 2019, 134
  • [10] Evaluation and critical assessment of putative MCL-1 inhibitors
    Varadarajan, S.
    Vogler, M.
    Butterworth, M.
    Dinsdale, D.
    Walensky, L. D.
    Cohen, G. M.
    CELL DEATH AND DIFFERENTIATION, 2013, 20 (11): : 1475 - 1484
12345